GLP-1 agonists (also known as GLP-1 receptor agonists) represent a class of medications used to treat type 2 diabetes...
New Studies Show the Potential of Semaglutide for Treating Alcohol Use Disorder and Knee Pain
read more
Alvotech’s Biosimilars Sales Drive 4-Fold Revenue Increase
On 13 November 2024, Alvotech announced its financial results for the first 9 months of 2024, reporting an increase in...
BioNTech to Acquire Biotheus and Investigational Bispecific Antibody Targeting PD-L1 and VEGF-A
On 13 November 2024, BioNTech announced that it has entered a definitive agreement to acquire Biotheus together with...
FDA Grants Breakthrough Therapy Designation for J&J’s Nipocalimab
On 11 November 2024, Johnson & Johnson (J&J) announced that the US FDA has granted nipocalimab Breakthrough...
J&J Seeks US and EU Approvals for New Daratumumab Indications
On 8 November 2024, Johnson & Johnson (J&J) announced that it has submitted applications to the US FDA and...
Alteogen Partners with Daiichi Sankyo on SC Enhertu® in US$300M Deal
On 8 November 2024, Korea Biomedical Review reported that Alteogen has signed an exclusive licence agreement with...
Celltrion’s Quarterly Sales at Record High
On 8 November 2024, Celltrion announced that it has achieved accumulated sales for Q3 2024 of KRW 2.4 trillion,...
Daiichi Sankyo and AstraZeneca Awarded Prix Galien Best Biotechnology Product Award for Enhertu®
On 7 November 2024, the Galien Foundation awarded Daiichi Sankyo and AstraZeneca the Prix Galien USA Award for Best...
Dupixent® EU Approved for Children with Eosinophilic Esophagitis
On 6 November 2024, Regeneron and Sanofi announced that the EC, as recommended by CHMP, has approved Dupixent®...
India’s SEC Recommends Approval of BMS’ Opdivo® for Unresectable or Metastatic Urothelial Carcinoma
India’s Subject Expert Committee (SEC) has recommended the approval of an additional indication for BMS’ Opdivo®...
Novo Nordisk Reports Strong Financial Performance
Novo Nordisk has reported strong financial performance for the first nine months of 2024. According to a 6 November...
Celltrion Announces Results of Preclinical Studies of Two New ADC Drug Pipelines
On 6 November 2024, Celltrion announced that it participated in the World ADC 2024 conference where it unveiled...
Amgen Secures Approval for 5 Additional Denosumab Brands in Australia
On 5 November 2024, the Australian Register of Therapeutic Goods (ARTG), published 5 approvals of new brands for...
Blockbuster Copies and Expansions Ahead in AU – Saxenda®, Opdivo®, Ozempic® & More
Australia’s Therapeutic Goods Administration (TGA) has updated its online list of prescription medicines for...
Alvotech/Advanz Announce EMA Acceptance for Biosimilar to J&J’s Simponi® (Golimumab) Confirming World First
On 4 November 2024, Alvotech and Advanz Pharma announced that the European Medicines Agency (EMA) has accepted their...
Telehealth Provider Plans to Offer Generic Liraglutide in the US From 2025
NYSE-listed telehealth provider, Hims & Hers Health Inc, announced in its third quarter 2024 earnings conference...